ocal effect of Metformin gel 1% in Periodontal treatment of patients with Type II Diabetes Mellitus and Periodontitis
- Conditions
- Diabetes mellitus
- Registration Number
- RBR-2c3t8gb
- Lead Sponsor
- Centro de Ciências Biológicas e da Saúde CCBS - Universidade Estadual do Oeste do Paraná
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruitment completed
- Sex
- Not specified
- Target Recruitment
- Not specified
Patients of both sexes with Periodontitis stages 1, 2, 3 or 4, grade B or C, presenting bleeding on probing and gingival inflammation. Patients must have the pathophysiological condition of Type II Diabetes Mellitus (diagnosed by endocrinologists) and use systemic Metformin. Patients who agree to participate in the study, signing the informed consent form. Patient aged between 18 and 70 years
Patients with a positive history in the last 6 months of broad-spectrum antibiotic therapy, steroidal anti-inflammatory drugs or immunosuppressive therapy in the 3 months prior to the study. Pregnant or lactating. History of periodontal treatment in the last 6 months. Smoking or quitting the habit for less than 5 months. Patients who have less than 4 teeth or have misaligned teeth in the dental arch. Patient under 18 years old or over 70 years old
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Expected Outcome 1: It is expected to improve the clinical parameters of clinical probing depth and clinical attachment level, decrease the amount of interleukin-17 present in the crevicular fluid.
- Secondary Outcome Measures
Name Time Method o secondary outcomes are expected